Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24603042 | 0.86 | TAS1R3 (0.47) | TAS1R3TAS1R1GAACHRNB2CHRNB4 | |
| SCHEMBL8031100 | 0.83 | ALDH1A1 (0.50) | TAS1R3TAS1R1GAACHRNB2CHRNB4 | |
| SCHEMBL25947506 | 0.83 | ALDH1A1 (0.50) | TAS1R3TAS1R1GAACHRNB2CHRNB4 | |
| SCHEMBL23722464 | 0.81 | CHRNB2 (0.42) | TAS1R3TAS1R1GAACHRNB2CHRNB4 | |
| SCHEMBL23095373 | 0.81 | ADH1B (0.42) | TAS1R3TAS1R1EPHX1MEN1KMT2A | |
| SCHEMBL23095392 | 0.80 | CHRNB2 (0.40) | TAS1R3TAS1R1GAACHRNB2CHRNB4 | |
| SCHEMBL19119593 | 0.80 | CHRNB2 (0.40) | TAS1R3TAS1R1GAACHRNB2CHRNB4 | |
| SCHEMBL20807998 | 0.80 | CHRNB2 (0.40) | TAS1R3TAS1R1GAACHRNB2CHRNB4 | |
| SCHEMBL22595052 | 0.78 | TAS1R3 (0.58) | TAS1R3TAS1R1MMP1MMP2GAA | |
| SCHEMBL4907351 | 0.78 | TAS1R3 (0.62) | TAS1R3TAS1R1MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10172868-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180125855-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172868-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | TAS1R3 4405/4885TAS1R1 4516/4885MMP1 4458/4885 |
| US-20180125855-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | TAS1R3 4405/4885TAS1R1 4516/4885MMP1 4458/4885 |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | TAS1R3 4260/4885TAS1R1 4318/4885MMP1 427/4885 |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | CDK3, CDK14, CDK1 | TAS1R3 4656/4885TAS1R1 4844/4885MMP1 1621/4885 |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | TAS1R3 4656/4885TAS1R1 4844/4885MMP1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.